Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the development of atherosclerosis and heart failure caused by ischemic conditions. Preclinical data from in vitro and in vivo studies suggest a protective role of pharmacological p38 inhibition with regard to the development of cardiovascular diseases. This article evaluates the therapeutic potential of this new pharmacological approach and discusses the current clinical data on Losmapimod.
© Georg Thieme Verlag KG Stuttgart · New York.